Advances in conditioning, graft-versus-host disease (GVHD) prophylaxis and antimicrobial
prophylaxis have improved the safety of allogeneic hematopoietic cell transplantation (HCT) …

Close HLA matching of donors and recipients has been the dogma for successful allogeneic
blood or marrow transplantation (alloBMT), to limit the complications of graft-versus-host …

Reducing the incidence of graft-versus-host disease (GVHD) after haploidentical
hematopoietic stem cell transplantation (HSCT) is warranted. Posttransplant …

Allogeneic blood and marrow transplantation (alloBMT) is increasingly being used in older
patients with blood cancer. Aging is associated with an increasing incidence of clonal …

Haploidentical stem cell transplantation (Haplo-SCT) using non-myeloablative conditioning
regimen (NMAC) has extended the feasibility of allogeneic transplantation, notably in older …

The successful application of post-transplantation cyclophosphamide (PTCy) as graft-versus-
host disease (GVHD) prophylaxis in HLA-haploidentical allogeneic hematopoietic cell …

We describe outcomes after post-transplantation cyclophosphamide and nonmyeloablative
conditioning-based allogeneic blood or marrow transplantation for myelofibrosis using …

High-dose post-transplantation cyclophosphamide (PTCy) is an effective platform for
prevention of severe graft-versus-host disease (GVHD) after allogeneic bone marrow (BM) …

Myelodysplastic syndrome (MDS) is a very heterogeneous clonal disorder. Patients with
“higher-risk” MDS, defined by specific recurrent genetic abnormalities, have a poor …

We retrospectively evaluated the incidence, factors, and clinical outcomes of the
discontinuation of immunosuppressive treatment (IST) after single-unit unrelated cord blood …